Asston Pharmaceuticals Limited has fulfilled its regulatory compliance obligations by submitting the mandatory quarterly certificate under SEBI regulations to BSE Limited. The submission relates to the quarter ended 31st March, 2026, marking the completion of Q4FY26 compliance requirements.

Regulatory Submission Details

The certificate was submitted on 14th April, 2026, by Company Secretary and Compliance Officer Rishi Upadhaya to BSE Limited's Listing and Compliance Department. The submission was made pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly reporting of dematerialisation activities.

Certificate Preparation and Verification

The compliance certificate was prepared by Maashitla Securities Private Limited, the company's appointed Registrar and Share Transfer Agent. Maashitla Securities, a SEBI Registered Category-I RTA with registration number INR000004370, issued the certificate on 4th April, 2026, confirming compliance with regulatory requirements.

The certificate was signed by Mukul Agrawal, Authorized Signatory of Maashitla Securities Private Limited, and digitally signed by Rishi Upadhaya on behalf of Asston Pharmaceuticals Limited.

Dematerialisation Activity Report

The quarterly report reveals no dematerialisation activity during the covered period. The compliance certificate confirms that no securities certificates were processed for dematerialisation between 1st January, 2026 to 31st March, 2026.

Company Information

Asston Pharmaceuticals Limited, formerly known as Asston Pharmaceuticals Private Limited, operates from its registered office located at 4th Floor Office No A-431 Balaji Bhavan, Plot No 42A Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra. The company holds CIN number U24304MH2019PLC324187 and maintains its corporate website at www.asstonpharmaceuticals.com .

The submission of this compliance certificate demonstrates the company's commitment to maintaining regulatory adherence and transparent reporting practices as required under SEBI regulations for listed entities.

Asston Pharmaceuticals Limited has officially confirmed the record date for its Extraordinary General Meeting (EGM) scheduled for April 28, 2026, at 12:30 P.M. The company has set April 17, 2026, as the cut-off date for determining shareholder eligibility to participate in the voting process, in compliance with regulatory requirements.

Meeting Details and Voting Arrangements

The EGM will be conducted through video conferencing in compliance with regulatory guidelines and will address several important corporate governance matters. Remote e-voting will be available through NSDL's platform from April 23, 2026, at 09:00 A.M. to April 27, 2026, at 05:00 P.M.

Regulatory Compliance Framework

The meeting follows provisions under Section 108 of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014, and Regulation 44 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The company has arranged e-voting facility through National Securities Depository Limited (NSDL) for members to participate in the business transactions.

Agenda Items for Approval

The EGM will consider four key resolutions covering auditor appointment and director regularizations. The primary agenda involves appointing M/s Panchal SK & Associates, Chartered Accountants (Firm Registration No. 145989W), as statutory auditors to address the casual vacancy created by the resignation of M/s. Doshi Doshi & Co., Chartered Accountants.

Participation Guidelines

The meeting follows Ministry of Corporate Affairs guidelines allowing virtual meetings through video conferencing. The facility will accommodate at least 1,000 members on a first-come, first-served basis, excluding large shareholders, promoters, institutional investors, and key personnel who have unrestricted access. M/s Praggya & Associates, Company Secretaries, has been appointed as scrutinizer for the e-voting process to ensure fair and transparent voting procedures.